AbClon

Beta

KRX Filings & Disclosures 2026

Business Overview

• • Core business: antibody biopharmaceuticals, including biosynergy and biounique antibodies
• • AffiMab bispecific antibody platform co-developed with Affibody, combining Affibody proteins with antibodies for enhanced stability and efficacy

Risk Factors

• • Foreign currency net asset exposure USD KRW 272.4M, EUR KRW 120.4M as of FY2025 quarter-end
• • 10% KRW appreciation/depreciation impacts pre-tax profit/loss by ±KRW 39.3M at FY2025 quarter-end

Management Discussion & Analysis

• • Revenue KRW 4.714B, +101.5% YoY; operating loss KRW 17.636B (-KRW 2.047B YoY); net loss KRW 17.907B (-KRW 1.605B YoY)
• • Operating loss increase driven by R&D costs for antibody and CAR-T pipeline development including AC101 Phase 3 and AT101 Phase 2 clinical trials

What are the latest AbClon DART filings in 2026?

AbClon (KRX code 174900) has filed an annual report on March 13, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did AbClon file its most recent annual report?

AbClon filed its most recent annual report on March 13, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is AbClon's KRX stock code?

AbClon's KRX stock code is 174900. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 174900 to look up all AbClon disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does AbClon file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for AbClon.

Where can I find AbClon financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from AbClon annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.